|
|
 |
 |
| |
Successfully developing Pharmaceuticals for the European Market
A new study by DAFSA, Global Insight's European market research centre.
Successfully developing Pharmaceuticals for the European Market is a comprehensive analysis of how to gain access to 19 European pharmaceutical markets. The study assesses which markets in Europe a) are most easily accessible for drug manufacturers, b) provide the best reimbursement coverage in terms of public or private healthcare insurance, and c) offer the most attractive pricing environment.
A DAFSA team carried out extensive primary research including over 50 in-depth interviews of national stakeholders (drug evaluation bodies, pricing authorities, representatives of the industry & insurance sector in ach country analyzed), combined with extensive analysis of drug prices in the "Big Five" European markets by therapeutic area (ATC 3 levels) and systematic cross-country analysis of the marketing authorisation, price fixing and reimbursement listing procedures in the 19 countries studied in the report.
The study is unique in its comprehensive European coverage, its focus on cross-country comparative analysis and its inclusion of the private healthcare system in its assessment of market potential. The depth of the study, its focus on market access and its extensive European coverage make this report an ideal complement to Global Insight's Pharmaceutical Pricing & Reimbursement Analysis service.
For more information, please visit www.dafsa.fr (site in French) or contact:
|
|
